Latest News

Water vapor thermal therapy also provided greater QoL improvement vs combination pharmacotherapy while preserving sexual function.

Urology practices should prepare for more than a simple payment cut in 2027, according to Jonathan Rubenstein, MD; and Mark Painter.

Kari Tikkinen, MD, PhD, discusses POISE-3 findings showing tranexamic acid reduced major bleeding without significantly increasing thrombotic events in urologic surgery.

Susanne Quallich, PhD, ANP-BC, NP-C, discusses APP leadership, specialization, professional growth, and expanding the role of APPs in urology.

Mary Dunn, MSN, NP-C, OCN, RN, highlights advances in advanced prostate cancer, including earlier systemic therapy, PSMA-PET, and PARP inhibitors.

Scott Bauer, MD, ScM, discusses an N-of-1 trial showing heterogeneous responses to long-term tamsulosin, identifying older men who may be candidates for deprescribing.

The designations were based on preliminary clinical data with 68Ga-NYM096, including a small, multicenter study presented at ASCO 2026.

Hans Arora, MD, PhD, discusses how communication and collaborative leadership can strengthen teamwork and performance in the operating room.

The phase 2 RadiCaL trial found that adding radium-223 to cabozantinib did not improve skeletal event-free survival in metastatic renal cell carcinoma.

Daniel S. Kellner, MD, discusses patient selection for HoLEP and strategies for surgeons interested in adoption.

The NDA submission is supported by data from the phase 3 UTOPIA trial.

Ryan K. Flannigan, MD, discusses phase 2 data showing promising efficacy with sustained-release lidocaine in men with chronic scrotal pain.

A recent study found active surveillance use for low-risk prostate cancer rose from 27% to 93% among veterans from 2005 to 2024.